DE111 clinical trials
Also written DE111®.
How each study uses DE111 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2020 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Santen Pharmaceutical Co., Ltd. (3) · The Archer-Daniels-Midland Company (1) · Deerland Enzymes (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)
Studies
Open first, then newest update. How each study uses DE111 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Digestion of Gluten in the Presence of EnzymesCompletedNot applicableThe Archer-Daniels-Midland CompanyNCT04489810Written as DE111®
- Gut Microbiome in OrthopaedicsWithdrawnNot applicableLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT06371950Written as Probiotic Formula Bacillus subtilis
- GlutDigest - Pilot StudyCompletedNot applicableDeerland EnzymesNCT04489836Written as DE111®
- DE-111 Against Timolol Ophthalmic Solution 0.5%CompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01342094Written as DE-111 ophthalmic solution
- DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01343082Written as DE-111 ophthalmic solution
- DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%CompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01342081Written as DE-111 ophthalmic solution